Background: Acute Leukemia is the most common childhood cancer, with two main types: ALL and AML. In Tanzania, recent improvements in treatment and survival have been noted, but the latest data is from 2013. This study will update survival and relapse information from 2013 to 2020 to help enhance future treatment strategies. Methodology: This study was conducted at two tertiary hospitals in Tanzania. The study analyzed data from children diagnosed with Acute Leukemia between January 2015 to December 2020. Patient data were collected via questionnaires and analyzed using STATA software. Results: This study included a total of 95 participants 64 had age less than 10 years and majority were males 56.8%, 55 had duration of symptoms for more than 1 month 66 had ALL, 49 had attained remission, the overall three years survival was 44.2% with those children with no health insurance having high risk of dying, rate of relapse was 18.4%, with those diagnosed with B-ALL having low risk of relapse. Conclusion: This study provides insights into survival and relapse predictors for childhood leukemia in northern Tanzania. It found an overall survival rate of 44.2%, with health insurance and minimal residual disease after induction being key predictors of survival. The relapse rate was 18.4%, with health insurance linked to a lower relapse risk. Health insurance emerged as a strong predictor of better survival, leading to the recommendation that all children should have health insurance. Additionally, the study suggests that policymakers should support the expansion of global health coverage in Tanzania.
References
[1]
Seth, R. and Singh, A. (2015) Leukemias in Children. The Indian Journal of Pediatrics, 82, 817-824. https://doi.org/10.1007/s12098-015-1695-5
[2]
Huang, J., Chan, S.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., et al. (2022) Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis. Frontiers in Oncology, 12, Article 904292. https://doi.org/10.3389/fonc.2022.904292
[3]
Kakaje, A., Alhalabi, M.M., Ghareeb, A., Karam, B., Mansour, B., Zahra, B., et al. (2020) Rates and Trends of Childhood Acute Lymphoblastic Leukaemia: An Epidemiology Study. Scientific Reports, 10, Article No. 6756. https://doi.org/10.1038/s41598-020-63528-0
[4]
Desandes, E., Clavel, J., Berger, C., Bernard, J., Blouin, P., de Lumley, L., et al. (2004) Cancer Incidence among Children in France, 1990-1999. Pediatric Blood & Cancer, 43, 749-757. https://doi.org/10.1002/pbc.20148
[5]
Linaberry, A.M. and Ross, J.A. (2007) Trends in Childhood Cancer Incidence in the U.S. (1994-2004). Cancer, 112, 416-432. https://doi.org/10.1002/cncr.23169
[6]
Bao, P., Zheng, Y., Wang, C., Gu, K., Jin, F. and Lu, W. (2009) Time Trends and Characteristics of Childhood Cancer among Children Age 0-14 in Shanghai. Pediatric Blood & Cancer, 53, 13-16. https://doi.org/10.1002/pbc.21939
[7]
Al-Hashimi, M. (2021) Incidence of Childhood Leukemia in Iraq, 2000-2019. Asian Pacific Journal of Cancer Prevention, 22, 3663-3670. https://doi.org/10.31557/apjcp.2021.22.11.3663
[8]
Eden, T. (2010) Aetiology of Childhood Leukaemia. Cancer Treatment Reviews, 36, 286-297. https://doi.org/10.1016/j.ctrv.2010.02.004
[9]
Okello, C.D., Niyonzima, N., Ferraresso, M., Kadhumbula, S., Ddungu, H., Tarlock, K., et al. (2021) Haematological Malignancies in Sub-Saharan Africa: East Africa as an Example for Improving Care. The Lancet Haematology, 8, e756-e769. https://doi.org/10.1016/s2352-3026(21)00198-8
[10]
Togo, B., Traore, F., et al. (2018) Childhood Acute Lymphoblastic Leukemia in Sub Saharan Africa: 4 Years? Experience at the Pediatric Oncology Unit Bamako, Mali. Journal of Child and Adolescent Health, 2, 24-26. https://doi.org/10.35841/child-health.2.2.24-25
[11]
Yao, J.J.A., Couitchere, L., Atimere, Y., Koné, D., Azagoh-Kouadio, R., Oulai, M.S., et al. (2012) Childhood Cancer in Côte D’ivoire, 1995-2004—Challenges and Hopes. South African Medical Journal, 103, Article 113. https://doi.org/10.7196/samj.6365
[12]
Ochicha, O., Gwarzo, A.K. and Gwarzo, D. (2012) Pediatric Malignancies in Kano, Northern Nigeria. World Journal of Pediatrics, 8, 235-239. https://doi.org/10.1007/s12519-012-0363-3
[13]
Mostert, S., Njuguna, F., Kemps, L., Strother, M., Aluoch, L., Buziba, G., et al. (2012) Epidemiology of Diagnosed Childhood Cancer in Western Kenya. Archives of Disease in Childhood, 97, 508-512. https://doi.org/10.1136/archdischild-2011-300829
[14]
Ssenyonga, N., Stiller, C., Nakata, K., Shalkow, J., Redmond, S., Bulliard, J., et al. (2022) Worldwide Trends in Population-Based Survival for Children, Adolescents, and Young Adults Diagnosed with Leukaemia, by Subtype, during 2000-14 (CONCORD-3): Analysis of Individual Data from 258 Cancer Registries in 61 Countries. The Lancet Child & Adolescent Health, 6, 409-431. https://doi.org/10.1016/s2352-4642(22)00095-5
[15]
Ganzel, C., Wang, X.V., Rowe, J.M., Richards, S.M., Buck, G., Marks, D.I., et al. (2020) At Three Years, Patients with Acute Lymphoblastic Leukaemia Are Still at Risk for Relapse. Results of the International MRC UKALLXII/ECOG E2993 Trial. British Journal of Haematology, 191, 37-43. https://doi.org/10.1111/bjh.16616
[16]
Joko-Fru, W.Y., Parkin, D.M., Borok, M., Chokunonga, E., Korir, A., Nambooze, S., et al. (2018) Survival from Childhood Cancers in Eastern Africa: A Population-Based Registry Study. International Journal of Cancer, 143, 2409-2415. https://doi.org/10.1002/ijc.31723
[17]
World Health Organization (2020) Framework: WHO Global Initiative for Childhood Cancer. Cure All Framework: WHO Global Initiative for Childhood Cancer: Increasing Access, Advancing Quality, Saving Lives.
[18]
Stones, D.K., De Bruin, G.P., Esterhuizen, T.M. and Stefan, D.C. (2014) Childhood Cancer Survival Rates in Two South African Units. South African Medical Journal, 104, Article 501. https://doi.org/10.7196/samj.7882
[19]
van Weelderen, R.E., Njuguna, F., Klein, K., Mostert, S., Langat, S., Vik, T.A., et al. (2021) Outcomes of Pediatric Acute Myeloid Leukemia Treatment in Western Kenya. Cancer Reports, 5, e1576. https://doi.org/10.1002/cnr2.1576
[20]
Mahmoud, M., Al Mahmasani, L., Charafeddine, M., Zahreddine, A., Moukalled, N., El Cheikh, J., et al. (2022) Impact of Insurance Status and Distance from Residence to Treatment Center on the Outcomes of Patients Diagnosed with Acute Myeloid Leukemia. Frontiers in Hematology, 1, Article 29. https://doi.org/10.3389/frhem.2022.1060029
[21]
Borowitz, M.J., Wood, B.L., Devidas, M., Loh, M.L., Raetz, E.A., Salzer, W.L., et al. (2015) Prognostic Significance of Minimal Residual Disease in High Risk B-ALL: A Report from Children’s Oncology Group Study AALL0232. Blood, 126, 964-971. https://doi.org/10.1182/blood-2015-03-633685
[22]
Berry, D.A., Zhou, S., Higley, H., Mukundan, L. and Fu, S. (2017) Association of Minimal Residual Disease with Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia—A Meta-Analysis. JAMA Oncology, 3, e170580.
[23]
Abdelmabood, S., Fouda, A.E., Boujettif, F. and Mansour, A. (2020) Treatment Outcomes of Children with Acute Lymphoblastic Leukemia in a Middle-Income Developing Country: High Mortalities, Early Relapses, and Poor Survival. Jornal de Pediatria, 96, 108-116. https://doi.org/10.1016/j.jped.2018.07.013
